I believe that is in part due to the shameless way it kept overbidding for AZN. Now all the market makers were set for the big fall and it didn't happen. So they need to bleed it and buy slowly to cover.
He is obviously confused about the payment date affecting the stock price. It of course is the X-Div date that affected the price. It really doesn't matter, it seems they are dumping and endless supply of stock on the ask daily. It is also pretty obvious that the company isn't buying stock here either. I thought it was a buy here, but forgot how easily the stock is manipulated.
Pfizer (NYSE:PFE)‘s stock had its “overweight” rating reiterated by equities researchers at JPMorgan Chase & Co. in a research report issued on Wednesday. They currently have a $35.00 price target on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 18.20% from the stock’s previous close.
I would hope it is over, but you can never believe Pfizer management. I think it is a buy here, but it may just linger or slide.
Pfizer (PFE) Crosses Pivot Point Resistance at $29.61
Published on Tue, 05/27/2014 - 09:28
By Robert Cotter in Pivot alerts, PFE, nyse:pfe, pfizer, pivot alerts
Shares of Pfizer (NYSE:PFE) opened today above their pivot of $29.52 and have already reached the first level of resistance at $29.61. Analysts will be watching for a cross of the next upside pivot targets of $29.73 and $29.94.
There is potential upside of 15.3% for shares of Pfizer based on a current price of $29.63 and an average consensus analyst price target of $34.17. The stock should run into initial resistance at its 200-day moving average (MA) of $30.45 and subsequent resistance at its 50-day MA of $30.71.
Over the past year, Pfizer has traded in a range of $27.12 to $32.96 and is now at $29.63, 9% above that low. The 200-day and 50-day moving averages have moved 0.02% higher and 0.85% lower over the past week, respectively.
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
Pfizer Coverage Initiated at Goldman Sachs (PFE)
Posted by Hasmir Abdula on May 27th, 2014 // No Comments
Share on StockTwits
Pfizer Inc. logoEquities researchers at Goldman Sachs started coverage on shares of Pfizer (NYSE:PFE) in a research report issued on Tuesday. The firm set a “buy” rating on the stock.
The President of what? Obama has no say in this matter. Of whom do you speak?
usually he bought leaps, but then started messing with selling PUTS etc. When did he last post? Was it on JCP? What aliases was he using?
All he does is make it more expensive to purchase . He should walk away , AZN stock would drop swiftly and the AZN shareholders would settle for less than the first offer,
They can buy nearly any company for peanuts compared to the proposed deal and get the same tax benefits. AZN stuck it's nose in the air and PFE should just walk away.
Pfizer (NYSE:PFE) had its price target increased by Citigroup Inc. from $31.00 to $36.00 in a research report sent to investors on Monday morning, Analyst Ratings Network reports.
I imagine the spammers believe there are enough dopes to take their information on scam shell stocks.
Sentiment: Strong Buy